Drug Combination Details
| General Information of the Combination (ID: C10359) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Celecoxib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [1] | ||
|
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [2] | |||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [3] | |||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [4] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CD1C | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Curcumin augmented the celecoxib-mediated antitumor effects in HepG2 cells. The addition of curcumin to celecoxib resulted in increased cytotoxicity and caspase-3 activation, ,reduced the levels of Akt, NF-kappaB, PGE2, MDA, CD1, and VEGF, as compared to CXB alone. | |||||
| Experiment 2 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| Caco-2 | CVCL_0025 | Colon adenocarcinoma | Homo sapiens | |||
| SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Curcumin potentiates the growth inhibitory effect of celecoxib. The synergistic growth inhibitory effect was mediated through a mechanism that probably involves inhibition of the COX-2 pathway and may involve other non-COX-2 pathways. | |||||
| Experiment 3 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Curcumin and celecoxib synergistically inhibited the growth of MDA-MB-231 cells. The synergistic growth inhibitory effect was mediated by a mechanism that possibly involves inhibition of the COX-2 pathways. | |||||
| Experiment 4 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | p34 | CVCL_UW54 | Pancreatic adenocarcinoma | Homo sapiens | ||
| MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Curcumin synergistically augments the growth inhibition inserted by celecoxib in pancreatic cancer cells expressing COX-2. The synergistic effect was mediated through inhibition of COX-2. | |||||
| Experiment 5 Reporting the Effect of This Combination | [2] | |||||
| In-vivo Model | Aberrant crypt foci (ACF) animal model was induced by subcutaneously injecting 0.2 ml DMH (30 mg/kg b.w.) in male, 6-week-old, F344 rats. | |||||
| Experimental
Result(s) |
Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. | |||||
